hVIVO plc (LSE:HVO), the London-based clinical research specialist best known for human challenge trials, is counting on a sharply firmer second half after reporting lower Revenue and a loss for the first six months of 2026. In interim results published on 15 September 2026, the company said its weighted contracted order book had more than doubled since the start of the year, although full-year revenue guidance was reduced because of project deferrals. The update has kept the group in focus among healthcare names on the FTSE AIM All Share Index.
What the Company Does
hVIVO runs human challenge clinical trials, in which volunteers are deliberately exposed to infectious agents under controlled conditions to test vaccines and antiviral treatments. It operates a Quarantine Facility in Canary Wharf, provides laboratory services including virology and molecular testing, and offers site and recruitment support for wider clinical trials. In August 2026 it acquired CRS Berlin, adding early-phase capabilities in dermatology and women's health.
Latest Developments
Revenue for the six months to 30 June 2026 fell to £16.3 million from £24.2 million, which the company attributed to the second-half weighting it had flagged at the start of the year. Chief Executive Yamin "Mo" Khan said the first half saw "a clear improvement in commercial momentum".
Key contract wins included a pivotal Phase III human challenge trial with ILiAD Biotechnologies for a whooping cough Vaccine candidate, described as hVIVO's largest such contract to date, and two influenza challenge contracts, one with Traws Pharma and another worth £6 million signed in May. After the period end, the company was also engaged for additional site and recruitment support on a Cidara programme, now part of MSD.
The CRS Berlin deal was struck for nominal upfront consideration of €25,000, with further payments equal to 18% of annual revenue for 2026 to 2028, subject to minimum thresholds. On the board, Chief Financial Officer Stephen Pinkerton retired on 30 September, with non-executive director Richard Cotton stepping in as interim finance chief.
Financial Picture
The group made an adjusted EBITDA loss of £4.5 million in the first half, compared with a £3.0 million profit a year earlier, and a loss for the period of £6.5 million. Cash stood at £13.0 million at 30 June, down from £14.3 million at the end of 2025. No Dividend was paid in the period.
The weighted contracted order book rose to £65 million from £30 million at the year end, or £72 million including CRS Berlin. Management expects second-half revenue to be roughly double the first half and positive adjusted EBITDA in the second half. Full-year revenue is now guided at about £47 million, including around £3 million from CRS Berlin, with a low single-digit adjusted EBITDA loss for the year, after some projects were deferred into 2027 and 2028.
Sector and index Context
hVIVO operates in the contract research market, where biotech funding conditions influence the timing of trial starts. Human challenge studies are a niche area, and the company positions itself as a leading provider. Within the FTSE AIM All Share Index, its results can swing significantly with contract timing.
Key Risks
The main risks include further deferrals of client studies, the concentration of revenue in a small number of large contracts, integration of CRS Berlin, cash consumption while the first-half loss is recovered, and the transition in the finance function following the CFO's retirement.
What to Watch Next
Investors will be watching for delivery against the roughly £47 million full-year revenue guidance, progress on the ILiAD Phase III trial, the appointment of a permanent chief financial officer and any new challenge study contracts as the company heads towards its full-year results for 2026.



_11_18_2026_06_43_20_247880.jpg)


Please wait processing your request...